Early safety check for potential sepsis clotting treatment

NCT ID NCT07176728

Recruiting now Knowledge-focused Sponsor: Bayer Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 25, 2026 · Updated 29 times

Summary

This early-stage study tests a new drug, BAY 3389934, in up to 16 healthy Japanese adults aged 18-55. The main goal is to check the drug's safety and how the body handles it at different doses. Participants receive either the drug or a placebo by IV infusion and are closely monitored for side effects. Results will help plan future studies for patients with a dangerous blood clotting problem caused by sepsis.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SEPSIS ASSOCIATED DISSEMINATED INTRAVASCULAR COAGULATION (DIC) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

SOUSEIKAI Fukuoka Mirai Hospital
RECRUITING

Fukuoka, Fukuoka Pref, 813-0017, Japan

Contact
SOUSEIKAI Fukuoka Mirai Hospital
RECRUITING

Fukuoka, 813-0017, Japan

Conditions

Explore the condition pages connected to this study.

SEPSIS ASSOCIATED DISSEMINATED INTRAVASCULAR COAGULATION (DIC)